22057 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Hudis
    Hudis
  4. Kris
    Kris
  5. Saltz
    Saltz
  6. Offit
    Offit
  7. O'Reilly
    O'Reilly
  8. Solit
    Solit
  9. Robson
    Robson
  10. Drilon
    Drilon

Groups

  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)
  7. Breast Medicine Service (4103)
  8. Surgery (4019)
  9. Department of Pathology and Laboratory Medicine (3422)
  10. Thoracic Oncology (3351)
  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer
    Meeting Abstract

    McArthur, H. L.; Page, D.; Proverbs-Singh, T.; Solomon, S.; Hudis, C.; Norton, L.; Patil, S.; Barrett, J. A.; Lebel, F.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer
    Meeting Abstract

    Elias, A. D.; Burris, H. A.; Patel, M. R.; Schwartzberg, L. S.; Richer, J. K.; Kavalerchik, E.; Stopatschinskaja, S.; Gibbons, J.; Markova, D.; Steinberg, J. L.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017
    Meeting Abstract

    Hyslop, T.; Alvarado, M.; Forero, A.; Golshan, M.; Hieken, T.; Horton, J.; Hudis, C.; McGuire, K.; Meric-Bernstam, F.; Nanda, R.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
    Meeting Abstract

    Hyman, D. M.; Piha-Paul, S. A.; RodoĢn, J.; Saura, C.; Puzanov, I.; Shapiro, G. I.; Loi, S.; Joensuu, H.; Hanrahan, A. J.; Modi, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab in the treatment of metastatic HER2-positive breast cancer after prior trastuzumab/pertuzumab- or pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Argolo, D.; Smyth, L.; Chen, M. F.; Hudis, C. A.; Dang, C. T.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling
    Meeting Abstract

    Gucalp, A.; Proverbs-Singh, T. A.; Razavi, P.; Chandarlapaty, S.; Patil, S.; Ross, D. S.; Zehir, A.; Baselga, J.; Hudis, C. A.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy-based regimens
    Meeting Abstract

    Chandarlapaty, S.; Sung, P.; Chen, D.; He, W.; Samoila, A.; You, D.; Bhatt, T.; Patel, P.; Voi, M.; Gnant, M.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2- advanced breast cancer
    Meeting Abstract

    Bardia, A.; Modi, S.; Oliveira, M.; Campone, M.; Ma, B.; Dirix, L.; Weise, A.; Nardi, L.; Zhang, V.; Bhansali, S. G.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
    Meeting Abstract

    Bardia, A.; Diamond, J. R.; Mayer, I. A.; Starodub, A. N.; Moroose, R. L.; Isakoff, S. J.; Ocean, A. J.; Guarino, M. J.; Berlin, J. D.; Messersmith, W. A.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Program evaluation of a female sexual medicine and women's health program
    Meeting Abstract

    Carter, J.; Seidel, B.; Stabile, C.; Baser, R.; Eaton, A.; Goldfarb, S.; Goldfrank, D.
    Cancer Research (2016)

    Fulltext@MSK | Save